Novavax Inc (NVAX)
$129.00 0.98 (0.75%)
14:11 EST NVAX Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 49.24B
PE Ratio -211.48
Volume (Avg. Vol.) 2.45M
Day's Range 127.91 - 135.71
52-Week Range 4.26 - 189.40
Dividend & Yield N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
- From InvestorPlace
- From the Web
NVAX stock is poised for returns once its Phase 3 trial results come out, but potential investors should keep their eyes on the news.
Novavax lost the race to be first with a Covid-19 vaccine, but NVX-CoV2373 is nearing approval. It will boost NVAX stock in 2021.
Phase 3 trial delays are pushing NVAX stock down, but the biotech still has a reliable vaccine candidate expected to generate $3.9 billion.
As Covid-19 vaccine leaders took the headlines, NVAX stock slipped into the shadows. However, the former group’s setbacks could spell upside opportunity for the latter.
Novavax is trailing the competition in the coronavirus vaccine race, but markets may be punishing NVAX stock too much.
NVAX stock has settled into a trading range. Wait for the resolution of these levels, then pounce with a trade.
If you're concerned over a regulatory bump in the road, relax, as Novavax stock should still have catalysts to drive the share price higher.
While Pfizer and Moderna enjoy first-to-market advantage, the reality is that being first in a vaccine race isn’t always the best. Plus, Novavax’s distinct approach could make NVAX stock a strong dark horse.
Bill Gates expects Novavax’s vaccine to be effective against Covid-19. Despite Pfizer being first, NVAX stock is still bound to benefit.
We’re again at the cusp of an amazing technological revolution that will carry the stock market to incredible new highs. Make sure to position yourself to take advantage of this huge profit potential.
NVAX stock is up over 3,000% this year yet it's not the one with the doses on the streets. Best to trade the stock while they chase the headline.
The development a Covid-19 vaccine is no longer a race to the finish line, but there are still plenty of reasons to buy NVAX stock.
It’s a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.
Novavax is up more than 33% in the last month, and at least one analyst believes NVAX stock has more than an 80% upside.
Four of six analysts call NVAX stock a buy. From where I sit, they’re spot on. Consider that in the first quarter of 2021, they expect the company to report a profit of $3.89 per share. I mean, wow.
NVAX stock has faltered lately, as other companies seem to have taken the lead in the Covid-19 vaccine race. But patience will be rewarded.
Novavax is in Phase 3 trials with its novel coronavirus vaccine and success there will provide massive momentum for NVAX stock.
It's tricky to pick a winner in the Covid vaccine race, but NVAX stock traders should know that there's room for more than one success story.
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader